Radiance Biopharma to Participate in 2025 BIO CEO & Investor Conference

February 11, 2025 03:04 AM AEDT | By EIN Presswire

Google News:

Radiance Biopharma to Participate in 2025 BIO CEO & Investor Conference — Image source: EIN Presswire

Recent News

What are next big copper projects? UBS tells when equipment makers cou...

EUR/USD poised to rack up more gains as ECB and Fed rate paths set to...

Carney launches ‘One Canadian Economy’ Act to unify trade, approvals

Trump signs orders to enhance drone defenses, support supersonic trave...

NEW YORK, NY, UNITED STATES, February 10, 2025 /EINPresswire.com/ -- Radiance Biopharma, a biotechnology company developing next generation Antibody Drug Conjugates (ADCs), announced it will attend and schedule meetings at the 2025 BIO CEO & Investor Conference taking place February 10-11, 2025 at the New York Marriott Marquis in New York City.

Management will be available to participate in one-on-one partnering meetings with registered investors and other conference attendees. Conference attendees that would like to schedule a meeting with the Company's management are encouraged to register through the BIO CEO attendee portal.

About Radiance Biopharma

Radiance is a biotechnology company developing next generation Antibody Drug Conjugates (ADCs) for the treatment of cancer. RB-164, is a ‘Best in Class’, anti-ROR-1 ADC, for the treatment of liquid and solid tumors. RB-201, is a ‘First in Class’ anti- HER2/TROP2 Bispecific ADC, utilizing next generation tandem linker-payload technology, for the treatment of solid tumors.

Contacts For more information, please visit www.radiancebiopharma.com Contact us at [email protected] Office Tel. 617.621.7143

Robert Brooks
Radiance Biopharma
email us here
Visit us on social media:
LinkedIn

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.